David Kickinger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
David Kickinger has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Anamarija Sutic
Department of Rheumatology and Immunology, Medical University of Graz, Graz, Austria
1 shared publication - Daniel Pietsch
Department of Rheumatology and Immunology, Medical University of Graz, Graz, Austria
1 shared publication - Florian Rainer
Klinische Abteilung für Gastroenterologie & Hepatologie, Universitätsklinik für Innere Medizin, Medizinische Universität Graz, Graz, Österreich
1 shared publication - Isabel Hodl
Department of Rheumatology and Immunology, Medical University of Graz, Graz, Austria
1 shared publication - Jens Thiel
Division of Rheumatology and Clinical Immunology, Medical University of Graz, Graz, Austria
1 shared publication - Martin Helmut Stradner
Department of Rheumatology and Immunology, Medical University of Graz, Graz, Austria
1 shared publication
Latest Publications
- Open Access
- 14 February 2026
- Published by Springer Nature in Rheumatology International
- Vol. 46 (3) , 47
Azathioprine as maintenance therapy for IgG4-related diseases: a retrospective case series and case-based review of the literature
IgG4-related disease (IgG4-RD) is a rare fibro-inflammatory disorder characterized by progressive fibrosis involving multiple organs and tissues. Clinical manifestations are highly variable, reflecting the organs affected. Oral glucocorticoids (GC) are established as first-line therapy; however, relapse occurs in 15–60% of patients. To reduce relapse risk and GC-related adverse effects, GC-sparing strategies using disease-modifying antirheumatic drugs (DMARDs) may be considered. This study aims to evaluate the efficacy and safety of azathioprine in the management of IgG4-RD and provides an overview of the current literature. This retrospective case series assesses disease activity under azathioprine therapy in patients with IgG4-RD treated at the Medical University of Graz between 2006 and 2024. Patients with a confirmed IgG4-RD diagnosis according to the 2019 ACR/EULAR criteria who received azathioprine following initial GC therapy were included. Ten male patients (mean age at disease onset: 59.4 years) with a mean follow-up of 75.2 months were analyzed. All patients fulfilled the 2019 ACR/EULAR classification criteria. Indications for initiating azathioprine included disease relapse on GC ( n = 3), GC-related adverse effects ( n = 3), and the intention to reduce GC exposure ( n = 7). During azathioprine therapy, three patients (30%) experienced a total of five relapses. Seven patients receiving azathioprine remained in remission throughout the observation period. Adverse events included infections ( n = 2), hematologic abnormalities ( n = 4), and elevated liver enzymes ( n = 1). At last follow-up, five patients (50%) remained on azathioprine, two (20%) had switched to rituximab, one of whom was in remission and off therapy, and three patients (30%) were no longer receiving immunosuppressive treatment (two due to hematologic abnormalities, one by patient request), with no further therapy initiated. Azathioprine represents an appropriate maintenance therapy for IgG4-RD. In cases with relapse under azathioprine, alternative DMARDs, such as CD19- or CD20-targeted therapies, may be more effective.
- 14 February 2026
- Published by Springer Nature in Rheumatology International
- Vol. 46 (3) , 47
Open AccessAzathioprine as maintenance therapy for IgG4-related diseases: a retrospective case series and case-based review of the literature
IgG4-related disease (IgG4-RD) is a rare fibro-inflammatory disorder characterized by progressive fibrosis involving multiple organs and tissues. Clinical manifestations are highly variable, reflecting the organs affected. Oral glucocorticoids (GC) are established as first-line therapy; however, relapse occurs in 15–60% of patients. To reduce relapse risk and GC-related adverse effects, GC-sparing strategies using disease-modifying antirheumatic drugs (DMARDs) may be considered. This study aims to evaluate the efficacy and safety of azathioprine in the management of IgG4-RD and provides an overview of the current literature. This retrospective case series assesses disease activity under azathioprine therapy in patients with IgG4-RD treated at the Medical University of Graz between 2006 and 2024. Patients with a confirmed IgG4-RD diagnosis according to the 2019 ACR/EULAR criteria who received azathioprine following initial GC therapy were included. Ten male patients (mean age at disease onset: 59.4 years) with a mean follow-up of 75.2 months were analyzed. All patients fulfilled the 2019 ACR/EULAR classification criteria. Indications for initiating azathioprine included disease relapse on GC ( n = 3), GC-related adverse effects ( n = 3), and the intention to reduce GC exposure ( n = 7). During azathioprine therapy, three patients (30%) experienced a total of five relapses. Seven patients receiving azathioprine remained in remission throughout the observation period. Adverse events included infections ( n = 2), hematologic abnormalities ( n = 4), and elevated liver enzymes ( n = 1). At last follow-up, five patients (50%) remained on azathioprine, two (20%) had switched to rituximab, one of whom was in remission and off therapy, and three patients (30%) were no longer receiving immunosuppressive treatment (two due to hematologic abnormalities, one by patient request), with no further therapy initiated. Azathioprine represents an appropriate maintenance therapy for IgG4-RD. In cases with relapse under azathioprine, alternative DMARDs, such as CD19- or CD20-targeted therapies, may be more effective.
- Open Access
- 11 June 2024
- Published by Springer Nature in rheuma plus
- Vol. 23 (6) , 341-347
Systemische Sklerose
Zusammenfassung: Bei der systemischen Sklerose (SSc) handelt es sich um eine komplexe, chronische Autoimmunerkrankung, die sowohl zu einer Fibrose der Haut als auch der inneren Organe führen kann. Die Prognose hinsichtlich des Verlaufs ist dabei sehr variabel und unter anderem abhängig von der Organbeteiligung. Die medikamentöse Therapie konnte unter anderem durch den Einsatz neuer Substanzen erweitert werden und dadurch kann beispielsweise die interstitielle Lungenbeteiligung, die mit einer erhöhten Mortalität einhergeht, besser behandelt werden. Dennoch stellt die SSc weiterhin eine Erkrankung mit einer hohen Mortalität und Morbidität dar und es sind zukünftige Studien für eine weitere Verbesserung der medikamentösen Therapie notwendig.
- 11 June 2024
- Published by Springer Nature in rheuma plus
- Vol. 23 (6) , 341-347
Open AccessSystemische Sklerose
Zusammenfassung: Bei der systemischen Sklerose (SSc) handelt es sich um eine komplexe, chronische Autoimmunerkrankung, die sowohl zu einer Fibrose der Haut als auch der inneren Organe führen kann. Die Prognose hinsichtlich des Verlaufs ist dabei sehr variabel und unter anderem abhängig von der Organbeteiligung. Die medikamentöse Therapie konnte unter anderem durch den Einsatz neuer Substanzen erweitert werden und dadurch kann beispielsweise die interstitielle Lungenbeteiligung, die mit einer erhöhten Mortalität einhergeht, besser behandelt werden. Dennoch stellt die SSc weiterhin eine Erkrankung mit einer hohen Mortalität und Morbidität dar und es sind zukünftige Studien für eine weitere Verbesserung der medikamentösen Therapie notwendig.